Goldman Sachs Group set a €82.00 ($101.23) price objective on Sanofi (EPA:SAN) in a research report sent to investors on Tuesday, January 23rd. The firm currently has a neutral rating on the stock.
SAN has been the topic of several other research reports. Morgan Stanley set a €92.00 ($113.58) price objective on shares of Sanofi and gave the stock a buy rating in a research note on Friday, October 6th. Berenberg Bank set a €97.00 ($119.75) target price on shares of Sanofi and gave the stock a neutral rating in a research note on Monday, January 22nd. Deutsche Bank set a €93.00 ($114.81) target price on shares of Sanofi and gave the stock a buy rating in a research note on Friday, January 19th. Barclays set a €65.00 ($80.25) target price on shares of Sanofi and gave the stock a sell rating in a research note on Tuesday, January 23rd. Finally, Jefferies Group set a €80.00 ($98.77) price objective on shares of Sanofi and gave the company a neutral rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of €82.82 ($102.25).
Sanofi (SAN) traded up €0.32 ($0.40) on Tuesday, reaching €63.89 ($78.88). Sanofi has a 52-week low of €63.09 ($77.89) and a 52-week high of €92.97 ($114.78). The firm has a market cap of $80,700.00 and a P/E ratio of 21.16.
ILLEGAL ACTIVITY NOTICE: “Sanofi (SAN) PT Set at €82.00 by Goldman Sachs Group” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/goldman-sachs-group-analysts-give-sanofi-san-a-82-00-price-target.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.